These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 20660377

  • 1. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
    Yagi S, Yoshikawa E, Futatsubashi M, Yokokura M, Yoshihara Y, Torizuka T, Ouchi Y.
    J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
    [Abstract] [Full Text] [Related]

  • 2. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
    Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M.
    Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
    [Abstract] [Full Text] [Related]

  • 3. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 4. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JO.
    J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
    [Abstract] [Full Text] [Related]

  • 5. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH.
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [Abstract] [Full Text] [Related]

  • 6. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, Rinne JO.
    Synapse; 2003 Jun 01; 48(3):109-15. PubMed ID: 12645035
    [Abstract] [Full Text] [Related]

  • 7. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr 01; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

  • 8. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
    Liu SY, Wu JJ, Zhao J, Huang SF, Wang YX, Ge JJ, Wu P, Zuo CT, Ding ZT, Wang J.
    Parkinsonism Relat Disord; 2015 Dec 01; 21(12):1448-53. PubMed ID: 26559130
    [Abstract] [Full Text] [Related]

  • 9. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism.
    Kim JM, Hong S, Kim GP, Choi YJ, Kim YK, Park SS, Kim SE, Jeon BS.
    Arch Neurol; 2007 Oct 01; 64(10):1510-8. PubMed ID: 17923635
    [Abstract] [Full Text] [Related]

  • 10. Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease.
    Li X, Zhang Q, Qin Y, Li Y, Mutaerbieke N, Zhao X, Yibulayin A.
    Medicine (Baltimore); 2020 Apr 01; 99(14):e19662. PubMed ID: 32243399
    [Abstract] [Full Text] [Related]

  • 11. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM.
    J Nucl Med; 2003 Jun 01; 44(6):855-61. PubMed ID: 12791810
    [Abstract] [Full Text] [Related]

  • 12. Microglial activation and dopamine terminal loss in early Parkinson's disease.
    Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T.
    Ann Neurol; 2005 Feb 01; 57(2):168-75. PubMed ID: 15668962
    [Abstract] [Full Text] [Related]

  • 13. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA.
    J Cereb Blood Flow Metab; 2006 Sep 01; 26(9):1198-212. PubMed ID: 16421508
    [Abstract] [Full Text] [Related]

  • 14. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.
    Nuklearmedizin; 2003 Feb 01; 42(1):31-8. PubMed ID: 12601452
    [Abstract] [Full Text] [Related]

  • 15. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O.
    Synapse; 2001 Jun 01; 40(3):193-200. PubMed ID: 11304757
    [Abstract] [Full Text] [Related]

  • 16. Adenosine A1 receptors measured with 11 C-MPDX PET in early Parkinson's disease.
    Mishina M, Ishii K, Kimura Y, Suzuki M, Kitamura S, Ishibashi K, Sakata M, Oda K, Kobayashi S, Kimura K, Ishiwata K.
    Synapse; 2017 Aug 01; 71(8):. PubMed ID: 28407307
    [Abstract] [Full Text] [Related]

  • 17. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P, Svenningsson P, Forsberg A, Jönsson EG, Amini N, Nakao R, Nag S, Halldin C, Farde L, Varrone A.
    J Nucl Med; 2015 May 01; 56(5):714-20. PubMed ID: 25791993
    [Abstract] [Full Text] [Related]

  • 18. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D.
    Neuroimage; 2004 Apr 01; 21(4):1497-507. PubMed ID: 15050574
    [Abstract] [Full Text] [Related]

  • 19. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I.
    J Neural Transm Suppl; 1997 Apr 01; 50():9-24. PubMed ID: 9120429
    [Abstract] [Full Text] [Related]

  • 20. Neuroinflammation in the living brain of Parkinson's disease.
    Ouchi Y, Yagi S, Yokokura M, Sakamoto M.
    Parkinsonism Relat Disord; 2009 Dec 01; 15 Suppl 3():S200-4. PubMed ID: 20082990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.